Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of VARIVAX in Healthy Russian Individuals 12 Months and Older
2019-003903-36Phase 3
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of varicella virus vaccine live in chickenpox, sponsored by Merck & Co. Primary endpoint: Varicella Zoster Virus (VZV) Antibody Response Rate.
02
Drugs
varicella virus vaccine live
03
Conditions
chickenpox
Beyond the preview
Go deeper on 2019-003903-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003903-36.